AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira follow-up

abbvie
Analysts expect to see AbbVie's Rinvoq generate more than $2 billion in 2023. (AbbVie)

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here.

On Friday, the FDA greenlighted Rinvoq, a rheumatoid arthritis med meant to succeed best-selling Humira as copycats bite into its sales. The new product should be available in the U.S. by late August, AbbVie said.

Rinvoq bears a list price of $59,000, which "is lower than the current leading treatments for moderate to severe rheumatoid arthritis," an AbbVie spokeswoman said by email. The company “continues to work closely with key stakeholders to support patient access to Rinvoq, including offering a patient support program and a co-pay card that may reduce out-of-pocket costs to $5 per month for eligible, commercially-insured patients," AbbVie said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Regulators based their decision on a phase 3 program dubbed Select, which featured 4,400 patients across five studies. Along the way, Rinvoq, which belongs to the up-and-coming JAK inhibitor class, showed it could top its anti-TNF predecessor in terms of efficacy.

“This is a very important data point for us in the program," as Rinvoq is the first JAK inhibitor to have a head-to-head study against an anti-TNF drug that was "able to show a prespecified superiority endpoint with multiple criteria,” Aileen Pangan, executive medical director of clinical development at AbbVie, said in an interview ahead of the approval.

RELATED: Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?

The JAK group hasn’t hit the scene without its issues, though. Blood clots have been reported across the class; in response, the FDA recently limited use of Pfizer’s Xeljanz in ulcerative colitis and added a Black Box warning to the drug’s label. For Rinvoq, a hemorrhagic stroke death and a pulmonary embolism—both in patients the pharma says had “pre-existing cardiovascular risk factors”—surfaced in phase 3.

Pangan, though, said investigators observed clots across every patient group in the Rinvoq trial, and that the rates of venous thromboembolism are "comparable” between the 15mg dose of Rinvoq and Humira.

“It is observed, but it’s a known risk in rheumatoid arthritis patients,” she said.

AbbVie’s hoping the med can overcome that obstacle to reach the $2.2 billion per year that analysts expect from the med by 2023. And while that haul will still fall far short of Humira’s numbers—the behemoth generated $4.8 billion globally in Q2 alone—it’ll go a long way for AbbVie in replacing sales lost to knockoff competition.

RELATED: AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Rinvoq won’t be taking on that task alone, either. In April, the Illinois pharma snagged a go-ahead for Skyrizi, a psoriasis-fighter that’s already making waves in the crowded field. After rolling out in May, the drug captured $48 million in second-quarter sales, soaring past Wall Street estimates to put up some of the best “launch numbers in my memory,” as Cowen & Co. analyst Steve Scala said on AbbVie’s earning conference call.

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.